Cardiovascular Systems, Inc. company was founded in 1989 and is based in Saint Paul, Minnesota. Cardiovascular Systems, Inc., a medical device company, focuses on developing and commercializing interventional treatment systems for vascular disease. Its primary product, the Diamondback 360°, is a minimally invasive catheter system for the treatment of peripheral arterial disease and a range of plaque types in leg arteries. The Diamondback 360° consists of a single-use catheter that travels over its proprietary ViperWire Guide Wire. The system is used in conjunction with a reusable external control unit.

BD Biosciences company, a division of medical equipment firm Becton, Dickinson (BD), provides research supplies to the life sciences market. Its primary Cell Analysis unit offers cell imaging devices, flow cytometers (for cell sorting), and chemical reagents and antibodies (proteins) for cellular analysis. The Discovery Labware unit makes basic lab supplies including pipettes, tubes, and cell culture kits. In addition to scientific researchers and drug developers, BD Biosciences counts among its customers blood banks, hospitals, and clinical labs. The company sells its goods around the world through direct and indirect marketing reps and independent distributors.

Generex Biotechnology Corporation company was founded in 1983 and is based in Toronto, Canada. Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. It develops a proprietary platform technology for the oral administration of large molecule drugs, including proteins, peptides, monoclonal antibodies, hormones, and vaccines. The company's products include Generex Oral-lyn, an insulin spray formulation used for the treatment of Type-1 and Type-2 diabetes; Glucose RapidSpray, which provides an alternative for people who require additional glucose in their diet, as well as delivers glucose formulation directly into the mouth; BaBOOM! Energy Spray, an instant energy spray designed to increase energy levels for sports, work, study, travel, and overall fatigue; and Crave-NX, a fat-free glucose spray that is used as an aid for dieters. Generex Biotechnology Corporation's under development products include medicinal chewing gum for the treatment of Type-2 diabetes mellitus and obesity; morphine and fentanyl products for breakthrough and postoperative pain; and AE37, an immunotherapeutic vaccine that is in Phase II clinical trials for patients with HER-2/neu positive breast cancer. The company markets its products through distributors and retail chains in Ecuador, Canada, and the United States. It has collaboration with Fertin Pharma A/S for the development of a metformin medicinal chewing gum.

Odyssey Thera researches new treatments for cancer and rheumatoid arthritis using its protein-fragment complementation assays (PCAs) to observe the action of small molecules and proteins. Essentially, it works to improve the speed and predictability of the drugs it studies. It technologies expedite the discovery and uses of drugs as well as track the development of new drug therapies. Odyssey partners with large drug makers such as Roche and Pfizer to profile selected compounds across its panel of assays to identify potential lead drug candidates. In 2005 it partnered with Bristol-Myers Squibb to analyze its compounds.

Trius Therapeutics is an early-stage biopharmaceutical company developing antibiotics to treat life-threatening bacterial infections. Torezolid phosphate, its most important drug in development, is an IV- and orally-administered antibiotic with a potential to treat antibiotic-resistant strains of staph infections, known as MRSA (methicillin-resistant Staphylococcus aureus). Until the company is able to sell torezolid phosphate to hospitals and other health care providers, the company is primarily funded by government grants, research contracts, and collaboration agreements. The company filed for an initial public offering in November 2009.

Laureate Pharma's protein purification and other production processes are pure poetry in motion. The contract manufacturing organization (CMO) develops, manufactures, and packages products used by pharmaceutical and biopharmaceutical companies to make drugs and diagnostics. The company's biopharmaceutical division specializes in making monoclonal antibodies and provides protein production and purification. Laureate also provides product formulation, aseptic filling, and bulk processing. It has partnerships with EMD Chemicals and GTC Biotherapeutics to provide products for clinical trials. Investment firm Safeguard Scientifics has sold its majority stake in Laureate Pharma to Saints Capital.

Boiron believes in nature's cures. The company makes homeopathic remedies to combat such maladies as colds, the flu, allergies, and anxiety. Founded in 1911, it is one of the oldest and largest such firms in Europe. It dominates its home market of France and also operates in Africa, Australia, North and South America, and the Middle East through about 20 subsidiaries. Along with homeopathic remedies, Boiron develops personal, animal care, and nutritional products for sale in some markets, including France (but not the US). One of the company's key products is Oscillococcinum six-dose homeopathic flu medicine. Used throughout the world, Oscillo is one of the largest homeopathic flu medicines in the US.

Panacea Pharmaceuticals, Inc. was founded in 1999 and is based in Gaithersburg, Maryland. Panacea Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic and diagnostic products for cancer and diseases of the central nervous system. It focuses on the development of proteins and biochemical pathways related to cellular regulation and cell cycle abnormalities in oncology, as well as neurodegenerative diseases such as stroke, Alzheimer's disease, and Parkinson's disease. The company’s products include PAN-22, a human anit-HAAH monoclonal antibody for treatment of hepatocellular carcinoma; PAN-622, a Toxin Conjugate to treat carcinoma of the bile duct; and PAN-811 for the treatment of ischemic stroke. In addition, it develops blood, serum, and tissue tests to diagnose and monitor breast, colorectal, lung, and prostate cancers, as well as gene expression test that predicts the response of patients with Chronic Myelogenous Leukemia to imatinib.

ACON Laboratories, Inc. company was founded in 1995 and is based in San Diego, California. ACON Laboratories has a contracted manufacturing facility located in Hangzhou, China. ACON Laboratories, Inc. engages in the custom product design and contract manufacturing of diagnostic healthcare products. It offers rapid test products for fertility, infectious diseases, and drugs of abuse, as well as provides tumor markers, cardiac markers, lateral flow immunoassay products, blood glucose monitoring systems, and urinalysis products. The company also provides urinalysis reagent strips, breath alcohol detectors, antibodies test kits, urine analyzers, antibody enzyme immunoassay (EIA) test kits, hepatitis B virus EIA test kits, hepatitis C virus antibody EIA test kits, syphilis antibody EIA test kits, antigen test devices, gonorrhea and Chlamydia test strips, gonorrhea test strips, and tuberculosis test devices. In addition, it offers diagnostic rapid test products, which are used to detect pregnancy, ovulation, menopause, HCV, HIV, helicobacter pyloris, malaria, and dengue. The company supplies its products to hospitals, clinical laboratories, blood banks, and consumer outlets. ACON Laboratories sells its products through independent medical distributors in Asia, the Middle East, Africa, the Russian Federation, and Latin America.

Nile Therapeutics, Inc. company was founded in 2005 and is based in San Mateo, California. Nile Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics for the treatment of cardiovascular disease and other areas of unmet medical needs. The company focuses on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure. CD-NP was designed to reduce symptoms of dyspnea in heart failure patients through both a reduction in intracardiac pressure and an improvement in renal function. Nile is also developing CU-NP, a novel, rationally designed natriuretic peptide.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.